Transcenta Holding Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Transcenta Holding (HKG:6628) Full Year 2023 Results

Key Financial Results

• Net loss: CN¥462.6m (loss widened by 14% from FY 2022).
• CN¥1.14 loss per share (further deteriorated from CN¥0.94 loss in FY 2022).

6628 Products In Clinical Trials

• Phase I: 7.
• Phase II: 2.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Transcenta Holding EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 56%. Earnings per share (EPS) exceeded analyst estimates by 21%.

Looking ahead, revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in Hong Kong.

Performance of the Hong Kong Biotechs industry.

The company's shares are up 30% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 5 warning signs with Transcenta Holding (at least 2 which shouldn't be ignored), and understanding them should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.